Javascript must be enabled to continue!
An Update on Eradication of Helicobacter Pylori in Iran: A Review
View through CrossRef
Background: Helicobacter pylori, the most prevalent infection in the world, has great importance due to being related to peptic ulcer disease, gastric metaplasia, dysplasia, and even gastric adenocarcinoma or mucosa-associated lymphoid tissue (MALT) lymphoma. The standard H. pylori eradication regimen is based on antibiotic susceptibility testing. If susceptibility testing is not available, a standard treatment regimen will be recommended based on records of H. pylori resistance rates to antibiotics in a region or locally proven highly effective regimens (equal to or higher than 90% eradication rate). The aim of this review was to define suitable recommendations for local treatment in different cities of Iran. Methods: This review article consists of randomized controlled trials related to H. pylori eradication in Iran. Data including the kind of therapy, number of patients and per-protocol H. pylori eradication rates were recorded in data gathering forms. Data search was conducted in PubMed and Google Scholar databases from 2018 to December 2023. Results: According to our review of Iranian articles regarding first-line H. pylori eradication regimens, these treatment protocols could be recommended: Bismuth-clarithromycin quadruple therapy in Ardabil, bismuth-clarithromycin quadruple therapy with probiotics in Birjand, standard triple therapy in Ilam, bismuth quadruple therapy or bismuth triple therapy or concomitant regimen in Sari, sequential therapy in Tehran and bismuth quadruple therapy in Yazd. These regimes can be extended to other regions that have a similar situation. According to the reports of Iranian researchers, a quinolone-containing regimen (levofloxacin preferred) is recommended for second-line eradication therapy. Conclusion: Various H. pylori eradication regimens can be used as first-line therapy; however, choices for second-line therapy are limited. We recommend the quinolone-containing regimens as the preferred second-line therapy.
Maad Rayan Publishing Company
Title: An Update on Eradication of
Helicobacter Pylori
in Iran: A Review
Description:
Background: Helicobacter pylori, the most prevalent infection in the world, has great importance due to being related to peptic ulcer disease, gastric metaplasia, dysplasia, and even gastric adenocarcinoma or mucosa-associated lymphoid tissue (MALT) lymphoma.
The standard H.
pylori eradication regimen is based on antibiotic susceptibility testing.
If susceptibility testing is not available, a standard treatment regimen will be recommended based on records of H.
pylori resistance rates to antibiotics in a region or locally proven highly effective regimens (equal to or higher than 90% eradication rate).
The aim of this review was to define suitable recommendations for local treatment in different cities of Iran.
Methods: This review article consists of randomized controlled trials related to H.
pylori eradication in Iran.
Data including the kind of therapy, number of patients and per-protocol H.
pylori eradication rates were recorded in data gathering forms.
Data search was conducted in PubMed and Google Scholar databases from 2018 to December 2023.
Results: According to our review of Iranian articles regarding first-line H.
pylori eradication regimens, these treatment protocols could be recommended: Bismuth-clarithromycin quadruple therapy in Ardabil, bismuth-clarithromycin quadruple therapy with probiotics in Birjand, standard triple therapy in Ilam, bismuth quadruple therapy or bismuth triple therapy or concomitant regimen in Sari, sequential therapy in Tehran and bismuth quadruple therapy in Yazd.
These regimes can be extended to other regions that have a similar situation.
According to the reports of Iranian researchers, a quinolone-containing regimen (levofloxacin preferred) is recommended for second-line eradication therapy.
Conclusion: Various H.
pylori eradication regimens can be used as first-line therapy; however, choices for second-line therapy are limited.
We recommend the quinolone-containing regimens as the preferred second-line therapy.
Related Results
The role of helicobacter pylori in coronary heart disease : laboratory, observational, and interventional studies
The role of helicobacter pylori in coronary heart disease : laboratory, observational, and interventional studies
<p dir="ltr"><b>Background</b></p><p dir="ltr">Helicobacter pylori (H. pylori) infects nearly half of the world's population and causes gastritis, pep...
The role of helicobacter pylori in coronary heart disease : laboratory, observational, and interventional studies
The role of helicobacter pylori in coronary heart disease : laboratory, observational, and interventional studies
<p dir="ltr"><b>Background</b></p><p dir="ltr">Helicobacter pylori (H. pylori) infects nearly half of the world's population and causes gastritis, pep...
Clinicopathological Characteristics and Endoscopic Features of Early Gastric Cancers Diagnosed After Helicobacter pylori Eradication
Clinicopathological Characteristics and Endoscopic Features of Early Gastric Cancers Diagnosed After Helicobacter pylori Eradication
Abstract
Background. Helicobacter pylori (H. pylori) infection is an important risk factor for developing gastric cancer. However, even after H. pylori eradication, early g...
THE CLINICAL CHARACTERISTICS, ENDOSCOPIC FINDINGS AND THE EFFICACY OF THE BISMUTH-CONTAINING QUADRUPLE REGIMEN INTREATMENT OF PATIENTS WITH HELICOBACTER PYLORIGASTRODUODENAL INFLAMMATORY AND ULCER AT CAN THO HOSPITAL OF UNIVERSITY OF MEDICINE AND PHARMACY
THE CLINICAL CHARACTERISTICS, ENDOSCOPIC FINDINGS AND THE EFFICACY OF THE BISMUTH-CONTAINING QUADRUPLE REGIMEN INTREATMENT OF PATIENTS WITH HELICOBACTER PYLORIGASTRODUODENAL INFLAMMATORY AND ULCER AT CAN THO HOSPITAL OF UNIVERSITY OF MEDICINE AND PHARMACY
Background: Helicobacter pylori causes inflammation of the gastric mucosa and is associated with many upper gastrointestinal diseases, including chronic gastritis, peptic ulcer dis...
Comparison of Efficacy of Conventional Triple Therapy and Non Bismuth Quadruple Therapy for Helicobacter Pylori Eradication
Comparison of Efficacy of Conventional Triple Therapy and Non Bismuth Quadruple Therapy for Helicobacter Pylori Eradication
Objective: To compare the efficacy of conventional triple therapy and non bismuth quadruple therapy for helicobacter pylori eradication. Setting: Gastroenterology Department, Lady ...
Helicobacter pylori infection and related factors among pregnant women at Debre Tabor General Hospital, Northwest Ethiopia, 2021
Helicobacter pylori infection and related factors among pregnant women at Debre Tabor General Hospital, Northwest Ethiopia, 2021
Abstract
Introduction: Infection with Helicobacter pylori is one of the most frequent chronic bacterial illnesses in humans, infecting more than half of the world's populat...
Effect of helicobacter pylori eradication on prognosis after gastrectomy for gastric cancer: A systematic review and meta-analysis.
Effect of helicobacter pylori eradication on prognosis after gastrectomy for gastric cancer: A systematic review and meta-analysis.
e16104
Background:
Gastric cancer is the fifth most common cancer and the fifth leading cause of cancer-related death worldwide. One o...
Non‐steroidal anti‐inflammatory drugs have bacteriostatic and bactericidal activity against Helicobacter pylori
Non‐steroidal anti‐inflammatory drugs have bacteriostatic and bactericidal activity against Helicobacter pylori
AbstractBackground: Helicobacter pylori infection and non‐steroidal anti‐inflammatory drugs (NSAIDs) are each associated with gastrointestinal mucosal damage, but the extent and ...

